The Challenge of Making Money from Biomarkers
This article was originally published in Start Up
Executive Summary
VCs won't go near traditional diagnostics. But some are starting to bet on biomarkers that expedite drug R&D and commercialization. Only one problem: they've yet to come up with the right business model